Monoclonal antibodies are lab-created proteins that mimic the immune system’s ability to fight off viruses and diseases. Bebtelovimab is a monoclonal antibody therapy directed against SARS-CoV-2, designed to block the virus’ attachment and entry into human cells. Currently, bebtelovimab is the only monoclonal antibody authorized for treatment of COVID-19.
The treatment is shown to:
Price: enter zip below to see local pricing
Returning customer? Click here to login
Monoclonal antibodies are lab-created proteins that mimic the ones our bodies produce to fight viruses. The antibodies defend the body by blocking Covid-19 viruses from attaching to human cells.
Bebtelovimab, pronounced: beb-te-LOV-i-mab
Bebtelovimab is a neutralizing antibody drug. When there’s a virus in your body, like COVID-19, your immune system makes antibodies to fight it off. But it takes time for your body to make antibodies for a new virus — and in the meantime, you could get very sick. Bebtelovimab contains man made antibodies to help fight the virus. They do not have any COVID-19 virus in them.
Bebtelovimab is NOT authorized for use in people who:
Bebtelovimab will be given as an injection through a vein (intravenously or IV) over at least 30 seconds. You will be observed for at least 1 hour after you receive bebtelovimab.
In order to ensure the safety and comfort of our patients, we offer this treatment in a house call setting.
Bebtelovimab has not been approved, but has been authorized for emergency use by the FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death and for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.
Yes. Eligibility for Monoclonal Antibody IV Treatment currently requires that you have recently tested positive for Covid-19.
How it works